

PYRVINIUM-DERIVED COMPOUNDS AND THEIR USE

A research group from CIBER, CSIC, Servicio Andaluz de Salud and Universidad de Sevilla relate the compounds of general formula (I), or to a pharmaceutically acceptable salt thereof, as well as to their use in therapy, especially as antibiotics and/or antiparasitics. The present invention also describes pharmaceutical compositions containing those compounds.

The Need

One of the greatest problems which humanity is facing nowadays is the multidrug resistance in bacteria, which is a dramatically increasing crisis. There is a strong need in society to design new therapeutic strategies against multidrug resistant bacterial infections.

The Solution

This new technology provides new treatment alternatives for bacterial (grampositive) and/or parasitic infections.

Innovative Aspects

The main innovative aspect of the method is the availability of new compounds with antibacterial and/or antiparasitic effect.

Pyrvinium derived compounds have shown antibacterial activity against a set of clinically relevant grampositive bacteria, including *Aerococcus urinae*, *Bacillus cereus*, *Corynebacterium amycolatum*, *Corynebacterium jeikeium*, *Corynebacterium urealiticum*, *Enterococcus faecalis*, *Enterococcus faecium*, *Fadklamia sp.*, *Listeria monocytogenes*, *Micrococcus luteus*, *Mycobacterium smegmatis*, *Schaalia radingae*, *Streptococcus agalactiae*, *Streptococcus pyogenes*, *Staphylococcus aureus*, *Staphylococcus epidermidis*.


Pyrvinium derived compounds have shown antiparasitic activity against a set of clinically relevant parasites, including *Trypanosoma* and *Leishmania* genus.

State of development:

Validated in *in vitro* bacteria and parasitic strains.

Intellectual Property:

Priority patent application filed.



Aims:

Looking for a partner interested in a license and/or a collaboration agreement to develop and exploit this asset.

Contact details: